|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0243125,
umls-concept:C0332181,
umls-concept:C0439234,
umls-concept:C0449258,
umls-concept:C0456603,
umls-concept:C0545661,
umls-concept:C0681842,
umls-concept:C0699900,
umls-concept:C1336645,
umls-concept:C1367028,
umls-concept:C1412836,
umls-concept:C1442488,
umls-concept:C1710303,
umls-concept:C2745888
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2010-8-11
|
|
pubmed:abstractText |
To determine to what extent baseline measurements of the ratio receptor activator of nuclear factor-kappaB ligand (RANKL):osteoprotegerin (OPG) and C-terminal cross linking of type-I and type-II (CTX-I and CTX-II), in addition to traditional markers of disease severity, could predict annual radiological progression.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen Type II,
http://linkedlifedata.com/resource/pubmed/chemical/Osteoprotegerin,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Procollagen,
http://linkedlifedata.com/resource/pubmed/chemical/RANK Ligand,
http://linkedlifedata.com/resource/pubmed/chemical/TNFRSF11B protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/TNFSF11 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/collagen II C-telopeptide,
http://linkedlifedata.com/resource/pubmed/chemical/collagen type I trimeric...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1468-2060
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1623-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20525836-Adult,
pubmed-meshheading:20525836-Antirheumatic Agents,
pubmed-meshheading:20525836-Arthritis, Rheumatoid,
pubmed-meshheading:20525836-Biological Markers,
pubmed-meshheading:20525836-Bone Resorption,
pubmed-meshheading:20525836-Cartilage Diseases,
pubmed-meshheading:20525836-Collagen Type I,
pubmed-meshheading:20525836-Collagen Type II,
pubmed-meshheading:20525836-Disease Progression,
pubmed-meshheading:20525836-Double-Blind Method,
pubmed-meshheading:20525836-Drug Therapy, Combination,
pubmed-meshheading:20525836-Female,
pubmed-meshheading:20525836-Follow-Up Studies,
pubmed-meshheading:20525836-Humans,
pubmed-meshheading:20525836-Male,
pubmed-meshheading:20525836-Middle Aged,
pubmed-meshheading:20525836-Osteoprotegerin,
pubmed-meshheading:20525836-Peptide Fragments,
pubmed-meshheading:20525836-Peptides,
pubmed-meshheading:20525836-Procollagen,
pubmed-meshheading:20525836-Prognosis,
pubmed-meshheading:20525836-RANK Ligand
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis.
|
|
pubmed:affiliation |
VU University Medical Center, Department of Rheumatology, De Boelelaan 1117, Amsterdam, The Netherlands. l.vantuyl@vumc.nl
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
